South Korea’s Celltrion Inks $744 Million Deal with U.S. Biotech, Eyeing Autoimmune Drug Market

Celltrion Inc., a global biopharmaceutical company based in South Korea, recently announced that it has entered into an exclusive licensing agreement with U.S. biotech firm Kaigene Inc. for two antibody-based drug candidates targeting autoimmune diseases. The total value exceeds one trillion Korean won (about US$744 million), including a 114 billion-won upfront payment.

Two Antibody Candidates Transferred to Celltrion

Celltrion acquired rights to Kaigene’s preclinical candidates KG006 and KG002. It holds exclusive global rights for KG006 (excluding China and Japan) and full global rights for KG002. Both aim to remove pathogenic autoantibodies, representing potential next-generation autoimmune therapies. 

Kaigene CEO Shin Min-jae, formerly head of antibody-drug development at HanAll Biopharma, brings experience in advancing candidates to clinical stage. The partnership strengthens Celltrion’s autoimmune-therapy portfolio and broadens its global reach.

Mechanisms of Action: FcRn Blockade and Dual Autoantibody Degradation

KG006 acts as a neonatal Fc receptor (FcRn) antagonist. It accelerates the clearance of pathogenic IgG antibodies from circulation. Normally, FcRn binds IgG in acidic endosomes and recycles it back into the bloodstream. This recycling extends IgG’s half-life to about 21 days. By blocking this pathway, KG006 triggers lysosomal degradation of IgG. As a result, pathogenic antibodies decline in diseases such as myasthenia gravis, immune thrombocytopenia (ITP), and lupus. Importantly, the process spares IgM and IgA, preserving innate immunity. Therefore, the immune system retains baseline defense while autoimmune activity decreases. Moreover, FcRn inhibitors such as efgartigimod (Vyvgart) and rozanolixizumab (Rystiggo) already validate this therapeutic strategy. Thus, KG006 fits within a proven mechanism with strong translational potential for antibody-mediated diseases.

KG002, by contrast, employs a dual mechanism of antibody degradation and B-cell suppression. It binds disease-specific autoantibodies and promotes their intracellular degradation. Simultaneously, it depletes autoreactive B cells that produce these antibodies. Consequently, both antibody load and upstream production decline. The molecule integrates Fc-engineering for antibody internalization with B-cell inhibition resembling anti-CD20 or BAFF-pathway drugs. Furthermore, this dual approach could extend remission periods and reduce dosing frequency. It addresses a key limitation of current monotherapies that require continuous administration or broad immunosuppression. Collectively, KG006 and KG002 represent a new class of antibody-degrading biologics. They aim to transform the treatment landscape for chronic and refractory autoimmune diseases by targeting both antibody persistence and immune cell sources.

Broader R&D Plan Targets 13 IND Filings by 2028

Celltrion will submit 13 investigational new-drug (IND) applications by 2028 under its “innovation-first” strategy. Current assets include ADCs CT-P70 and CT-P71 for non-small-cell lung and bladder cancers, both in Phase I. The company plans to start trials for CT-P72 (a multi-antibody immuno-oncology agent) and CT-P73 (an ADC drug) within 2025. 

Many projects rely on proprietary or co-developed platforms, such as the PBX-7016 payload from Pinotbio for low toxicity and high tumour inhibition. The effort marks Celltrion’s evolution from a biosimilar manufacturer into an innovation-driven drug developer.

Open Innovation Partnerships in Korea

Through its Open Innovation Program, Celltrion is collaborating with domestic biotechs to build Korea’s next-generation drug-development ecosystem. In line with this, it signed a ₩712.5 billion (≈ US$ 522 million) co-development deal with MustBio to create a tri-specific fusion-protein immuno-oncology drug targeting the PD-(L)1 market. MustBio will lead early discovery, molecular design, and animal-efficacy validation of a molecule simultaneously engaging PD-1, VEGF, and IL-2v (interleukin-2 variant) pathways, while Celltrion oversees process development, clinical trials, regulatory approval, and global commercialization.

In addition, Celltrion signed another agreement worth ₩125.9 billion (≈ US$ 87.8 million) with Portrai to apply spatial transcriptomics and AI technology for the discovery of up to ten new drug targets. In this deal, Portrai provides access to its high-resolution cancer-patient tissue database and AI-powered analysis platform (PortraiTARGET) that uses spatial transcriptomics to map gene-expression with spatial context in tumor microenvironments, while Celltrion obtains exclusive rights to discover and develop candidate substances against those targets and will lead subsequent preclinical and clinical development.

Global Footprint Strengthens Supply and Market Access

Celltrion is expanding global manufacturing and distribution to strengthen its integrated biopharma model. In the United States, it acquired Eli Lilly’s Branchburg, New Jersey facility for about US$330 million. The 37-acre, 391,000-sq-ft site will support KG002 and other biologics after validation, while continuing partial CMO work for Lilly. The deal mitigates tariff exposure and adds U.S. production capacity; Celltrion plans to invest up to ₩1.4 trillion (≈ US$1 billion) for upgrades.

Looking further, in Europe, Celltrion’s adalimumab biosimilar Yuflyma (CT-P17) has gained significant traction, holding 24 percent market share in major markets and over 52 percent in Italy, according to IQVIA data. Developed and manufactured entirely in-house, Yuflyma was the first high-concentration, citrate-free adalimumab formulation approved by the European Medicines Agency (EMA) in 2021. The results highlight Celltrion’s transition from distributor partnerships to a direct-sales model through its own subsidiary, Celltrion Healthcare, allowing tighter control over pricing, logistics, and market access across Europe.

Moreover, in Asia-Pacific, Celltrion broadened its portfolio by acquiring Takeda’s consumer-health assets in nine countries for up to US$278 million. The 18-product portfolio, spanning cardiovascular and metabolic therapies, provides steady regional revenue to fund high-risk R&D. Together, these initiatives expand Celltrion’s manufacturing footprint, commercial reach, and financial base for global biologics growth.

Evolving from Biosimilars to Broader Biopharma Innovation

The Kaigene deal and domestic R&D alliances signal Celltrion’s transition from a price-focused biosimilar producer to a broader innovation-driven biopharmaceutical company. Analysts note that upcoming clinical data from CT-P71, KG002, and the tri-specific fusion protein program will be key indicators of the company’s R&D productivity and long-term growth potential. Celltrion continues to report a cost-of-goods ratio below 40 percent, with a growing share of revenue from higher-margin biologics—resources it is channeling toward next-generation therapeutic development.

Related posts:

Taiwan’s Semiconductor Industry Steers Global Tech Amidst Economic Headwinds and Regionalization How Taiwan and Malaysia Are Rewiring AI, Data Sovereignty, and Industry China’s Biotech Industry Is Having Its Moonshot Moment Academia Sinica engineers first dual carbon-fixation plant system; “synthetic C2” boosts CO₂ capture, growth, and lipids

Author

Bernice Lottering